Empagliflozin mitigated tebuconazole-induced cardiomyocyte impairments, preventing increased cell contraction, resting membrane potential depolarization, and action potential prolongation.
Does empagliflozin mitigate tebuconazole-induced cardiotoxicity in isolated rat cardiomyocytes?
Empagliflozin mitigates tebuconazole-induced cardiomyocyte impairments, highlighting potential new pharmacological applications in pesticide-related cardiotoxicity.
AIMS: Tebuconazole (TEB) is a fungicide that has been increasingly associated with cardiovascular effects. The Sodium-Glucose Cotransporter-2 Inhibitors, as Empagliflozin (EMPA), have emerged as a therapeutic class with direct, independent, cardioprotective properties that extend beyond glycemic control. However, the mechanisms underlying these protective actions remain incompletely understood, particularly regarding whether EMPA can mitigate cardiotoxicity triggered by toxicants, as TEB. This study aimed to evaluate the potential action of EMPA during TEB exposure. MATERIALS AND METHODS: Cardiomyocytes from rats were isolated and divided as: control (vehicle), TEB, and TEB + EMPA (acute exposure). Contractility, action potential, calcium dynamics, and oxidative mechanisms were analyzed. Also, experimental structures of human and rat cardiac channels (Nav1.5, Cav1.2, and Kv4.2) were retrieved and used for high-exhaustiveness whole-protein docking of TEB and EMPA structures. KEY FINDINGS: EMPA prevented the increase in cell contraction induced by TEB. Moreover, EMPA inhibited TEB-induced depolarization of the resting membrane potential and action potential prolongation. TEB markedly impaired calcium handling in cardiomyocytes, rising transient amplitude and changing kinetics, whereas EMPA attenuated these disturbances. The alterations were not associated with oxidative mechanisms. Docking analyses revealed convergent and state-dependent binding patterns of TEB and EMPA across the ion channels. In conclusion, EMPA exposure mitigated TEB-induced cardiomyocyte impairments. There was a degree of superposition between the poses found for TEB and EMPA, which suggests that, even in different channels and in channels sites and respective states, they may compete for the same binding sites. SIGNIFICANCE: These findings highlight new pharmacological possibilities for EMPA, in pesticide-related cardiotoxicity.
Martins et al. (Fri,) conducted a other in Tebuconazole-induced cardiotoxicity. Empagliflozin vs. Control (vehicle) and Tebuconazole alone was evaluated on Electrocontractile function (contractility, action potential, calcium dynamics, and oxidative mechanisms). Empagliflozin mitigated tebuconazole-induced cardiomyocyte impairments, preventing increased cell contraction, resting membrane potential depolarization, and action potential prolongation.